![]() | Only 14 pages are availabe for public view |
Abstract Summary Acute myocardial infarction remains a leading cause of morbidity and mortality worldwide. It occurs when irreversible myocardial cell damage or death occurs. STEMI is caused by occlusion of major coronary artery and primary percutaneous coronary intervention is the preferred reperfusion strategy especially when performed by an experienced team within the shortest possible time from first medical contact. Activated platelets participate to produce inflammatory substances from endothelial cells and leucocytes that cause monocyte adhesion and thereby increase the inflammatory process and progression of atherosclerotic plaque. Lymphocyte play a dominant role in chronic inflammation of atherosclerosis, and lower lymphocyte count is associated with increased cardiovascular risk and mortality in acute myocardial infarction (AMI). In this study, we assessed the PLR as an indicator of nonereflow after PPCI in patient presented with STEMI. 100 patients were selected, in our institution, presented with STEMI, CBC (complete blood count) was done and platelet to lymphocyte ratio was calculated. PLR on admission was significantly higher in postintervention none-reflow group. There was a large number of diabetic patient in the none - reflow group. In conclusion, different from other inflammatory markers and assays, PLR is inexpensive and readily available biomarkers that may be useful as predictor of none reflow following PPCI in patients with STEMI. |